Skip to main content

Advertisement

SpringerLink
Log in

Prognostic Value of Metabolic Activity Measured by 18F-FDG PET/CT in Patients with Advanced Endometrial Cancer

  • Original Article
  • Published:
Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

We evaluated the potential prognostic value of 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) in patients with stage IIIC/IV endometrial cancer.

Methods

Patients with stage IIIC/IV endometrial cancer who had undergone FDG PET/CT workup for staging were enrolled. Maximum standardized uptake values (SUVmax) measured from regions of interest (ROIs) of the primary tumor (SUVt) and lymph nodes (SUVn) were correlated with overall survival (OS). The SUVn was defined as the highest SUVmax of the metastatic lymph nodes. Survival probability was assessed using the Kaplan-Meier method.

Results

A total of 42 patients with a median age of 55.5 years (range 32–76 years) were included. Twenty-nine percent (n = 12) of patients were premenopausal and 71 % (n = 30) were postmenopausal. The average SUVt was 12.9 (range 1.8–36.5), and the average SUVn was 7.3 (range 2.0–22.5). Median follow-up time was 25.9 months (range 1–84 months). Using a SUVt of 9.5 as a cutoff value, two groups with different rates were determined (P = 0.026). In addition, patients with a low SUVn had significantly better OS than those with a high SUVn (P = 0.003). Patients in the International Federation of Obstetrics and Gynecology (FIGO) stage IV group with SUVt ≥ 9.5 or SUVn ≥ 7.3 showed a significantly longer OS than the other groups.

Conclusions

FDG uptake of primary endometrial cancer and lymph nodes might be a prognostic factor in advanced endometrial cancer. More aggressive therapy could be considered in patients with stage IV endometrial cancer and high SUVt and/or high SUVn.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet. 2005;366:491–505.

    Article  PubMed  Google Scholar 

  2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.

    Article  PubMed  Google Scholar 

  3. Rose PG. Endometrial carcinoma. N Engl J Med. 1996;335:640–9.

    Article  PubMed  CAS  Google Scholar 

  4. Trope CG, Alektiar KM, Sabbatini PJ, et al. Corpus: epithelial tumors. In: Principles and practice of gynecologic oncology. 2005.

  5. Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer. 1987;60:2035–41.

    Article  PubMed  CAS  Google Scholar 

  6. Wong RJ, Lin DT, Schoder H, Patel SG, Gonen M, Wolden S, et al. Diagnostic and prognostic value of [(18)F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol. 2002;20:4199–208.

    Article  PubMed  CAS  Google Scholar 

  7. Minn H, Lapela M, Klemi PJ, Grenman R, Leskinen S, Lindholm P, et al. Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer. J Nucl Med. 1997;38:1907–11.

    PubMed  CAS  Google Scholar 

  8. Allal AS, Dulguerov P, Allaoua M, Haenggeli CA, el El-Ghazi A, Lehmann W, et al. Standardized uptake value of 2-[(18)F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol. 2002;20:1398–404.

    Article  PubMed  CAS  Google Scholar 

  9. Casasnovas RO, Meignan M, Berriolo-Riedinger A, Bardet S, Julian A, Thieblemont C, et al. SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood. 2011;118:37–43.

    Article  PubMed  CAS  Google Scholar 

  10. Itti E, Lin C, Dupuis J, Paone G, Capacchione D, Rahmouni A, et al. Prognostic value of interim 18F-FDG PET in patients with diffuse large B-cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med. 2009;50:527–33.

    Article  PubMed  Google Scholar 

  11. Scott AM, Gunawardana DH, Wong J, Kirkwood I, Hicks RJ, Ho Shon I, et al. Positron emission tomography changes management, improves prognostic stratification and is superior to gallium scintigraphy in patients with low-grade lymphoma: results of a multicentre prospective study. Eur J Nucl Med Mol Imaging. 2009;36:347–53.

    Article  PubMed  Google Scholar 

  12. Pan L, Gu P, Huang G, Xue H, Wu S. Prognostic significance of SUV on PET/CT in patients with esophageal cancer: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2009;21:1008–15.

    Article  PubMed  Google Scholar 

  13. Berghmans T, Dusart M, Paesmans M, Hossein-Foucher C, Buvat I, Castaigne C, et al. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol. 2008;3:6–12.

    Article  PubMed  Google Scholar 

  14. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–49.

    Article  PubMed  Google Scholar 

  15. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 2009;105:103–4.

    Article  PubMed  Google Scholar 

  16. Manetta A, Delgado G, Petrilli E, Hummel S, Barnes W. The significance of paraaortic node status in carcinoma of the cervix and endometrium. Gynecol Oncol. 1986;23:284–90.

    Article  PubMed  CAS  Google Scholar 

  17. Creasman W. Revised FIGO staging for carcinoma of the endometrium. Int J Gynaecol Obstet. 2009;105:109.

    Article  PubMed  Google Scholar 

  18. Maldonado A, Gonzalez-Alenda FJ, Alonso M, Sierra JM. PET-CT in clinical oncology. Clin Transl Oncol. 2007;9:494–505.

    Article  PubMed  CAS  Google Scholar 

  19. Song BI, Lee SW, Jeong SY, Chae YS, Lee WK, Ahn BC, et al. 18F-FDG uptake by metastatic axillary lymph nodes on pretreatment PET/CT as a prognostic factor for recurrence in patients with invasive ductal breast cancer. J Nucl Med. 2012;53:1337–44.

    Article  PubMed  CAS  Google Scholar 

  20. Lee M, Lee Y, Hwang K, Choe W, Park C. Usefulness of F-18 FDG PET/CT in assessment of recurrence of cervical cancer after treatment. Nucl Med Mol Imaging. 2011;45:111–6.

    Article  CAS  Google Scholar 

  21. Kim B, Kim I, Kim S-J, Nam H-Y, Pak K, Kim K, et al. The prognostic value of the metabolic tumor volume in FIGO stage IA to IIB cervical cancer for tumor recurrence: measured by F-18 FDG PET/CT. Nucl Med Mol Imaging. 2011;45:36–42.

    Article  CAS  Google Scholar 

  22. Liu FY, Chao A, Lai CH, Chou HH, Yen TC. Metabolic tumor volume by 18F-FDG PET/CT is prognostic for stage IVB endometrial carcinoma. Gynecol Oncol. 2012;125:566–71.

    Article  PubMed  Google Scholar 

  23. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer. 2002;2:683–93.

    Article  PubMed  CAS  Google Scholar 

  24. Vesselle H, Schmidt RA, Pugsley JM, Li M, Kohlmyer SG, Vallires E, et al. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res. 2000;6:3837–44.

    PubMed  CAS  Google Scholar 

  25. Buck A, Schirrmeister H, Kuhn T, Shen C, Kalker T, Kotzerke J, et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging. 2002;29:1317–23.

    Article  PubMed  CAS  Google Scholar 

  26. Boellaard R, Krak NC, Hoekstra OS, Lammertsma AA. Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med. 2004;45:1519–27.

    PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by the Students’ Association of the Graduate School of Yonsei University and funded by the Graduate School of Yonsei University.

Conflict of Interest

None.

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Yonsei University College of Medicine, 134 Shinchon-dong, Seodaemoon-gu, Seoul, 120-752, Korea

    Hyun Jeong Kim, Jiyoun Choi, Yong Hyu Jeong, Kwan Hyeong Jo, Jae-Hoon Lee, Arthur Cho, Mijin Yun, Jong Doo Lee & Won Jun Kang

  2. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Institute of Women’s Life Medical Science, Yonsei University College of Medicine, Seoul, Korea

    Young Tae Kim

Authors
  1. Hyun Jeong Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jiyoun Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yong Hyu Jeong
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kwan Hyeong Jo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jae-Hoon Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Arthur Cho
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mijin Yun
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jong Doo Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Young Tae Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Won Jun Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Won Jun Kang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim, H.J., Choi, J., Jeong, Y.H. et al. Prognostic Value of Metabolic Activity Measured by 18F-FDG PET/CT in Patients with Advanced Endometrial Cancer. Nucl Med Mol Imaging 47, 257–262 (2013). https://doi.org/10.1007/s13139-013-0228-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13139-013-0228-2

Keywords

Search

Navigation